# Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

> **NCT07017270** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Unity Health Toronto** · enrollment: 100 (estimated)

## Conditions studied

- Kidney Disease, Chronic
- Diabetes
- Dialysis
- End Stage Kidney Disease (ESRD)

## Interventions

- **DRUG:** Semaglutide Pen

## Key facts

- **NCT ID:** NCT07017270
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2027-07
- **Final completion:** 2027-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017270, "Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07017270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*